Investment Analysts’ Weekly Ratings Updates for Brainsway (BWAY)

Several analysts have recently updated their ratings and price targets for Brainsway (NASDAQ: BWAY):

• 12/22/2025 – Brainsway had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/13/2025 – Brainsway was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/8/2025 – Brainsway had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Brainsway had its price target raised by analysts at HC Wainwright from $18.00 to $24.00. They now have a “buy” rating on the stock.
• 12/1/2025 – Brainsway had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Brainsway was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/24/2025 – Brainsway had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/23/2025 – Brainsway was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/17/2025 – Brainsway had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/15/2025 – Brainsway was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/13/2025 – Brainsway had its price target raised by analysts at HC Wainwright from $17.00 to $18.00. They now have a “buy” rating on the stock.
• 11/12/2025 – Brainsway had its price target raised by analysts at Northland Securities from $19.00 to $23.00. They now have an “outperform” rating on the stock.
• 11/11/2025 – Brainsway had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.